A defensive, high-margin consumables compounder with a unique FDA foothold—Tristel’s US chlorine-dioxide foam rollout is the upside engine, and leadership/regulatory execution are the swing factors.
Overview
Tristel plc is a specialist infection prevention company focused on high-level disinfection (HLD) for medical devices and hospital environments, differentiated by its proprietary chlorine dioxide chemistry with decades of clinical use. It operates in a defensive, highly regulated niche where rapid point-of-care turnaround matters (ENT, cardiology, OB/GYN, ophthalmology, urology), enabling clinics to increase throughput without expensive automated reprocessors. The business model is highly recurring: in FY2025, >98% of revenue came from proprietary consumables required for each disinfection event, creating ‘non-discretionary’ repeat demand. Tristel is increasingly international (61% revenue outside the UK) and is expanding geographically via direct operations across Europe and beyond. The central upside is US market entry: FDA De Novo clearance for Tristel ULT (2023) created a new regulatory category, supporting strong early adoption and a scalable distribution partnership. Financially, the company combines high growth with exceptional margins and a debt-free balance sheet, though near-term execution risk is elevated due to an ongoing CEO transition.